Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote & News

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 238 8090

Website: eledon.com

Address:

19800 MacArthur Boulevard, Suite 250, Irvine, United States

BlakeLawrence90 Mar. 21 at 4:56 PM

$ELDN small biotech setup with squeeze risk and the tape needs to prove it with real flow

0 · Reply

Cosmoskeeper Mar. 21 at 12:09 AM

$ELDN trials 👍🏻

0 · Reply

goooooolddust Mar. 20 at 10:51 PM

$ELDN it's opex Day guys, I don't think it added anything more than to do with that

0 · Reply

red1 Mar. 20 at 10:33 PM

$ELDN $SANA $VRTX what do you guys think? Why such big moves?

1 · Reply

red1 Mar. 20 at 9:05 PM

$ELDN $VRTX $SANA All had massive volume spike at the end… big volume AH … I wonder why? Islet act? Partnership collab?

0 · Reply

Penny_stock_Raid_Boss Mar. 20 at 8:43 PM

$ELDN casual almost 1 milly shares gap up in post market.

0 · Reply

Veraton Mar. 20 at 8:12 PM

$ELDN first time around here...mmm 🤔

0 · Reply

red1 Mar. 20 at 8:08 PM

$ELDN speculation I could be wrong of course . Let’s hope someone knows a thing or two

0 · Reply

red1 Mar. 20 at 8:03 PM

$ELDN the share at the end were for calll options wich get exercised automatically at close

0 · Reply

Veraton Mar. 20 at 8:01 PM

$ELDN 1.6 million shares last 5 seconds before the bell... Somebody knows something

0 · Reply

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Mar 16, 2026, 1:47 PM EDT - 5 days ago

Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative

Mar 10, 2026, 7:00 AM EDT - 11 days ago

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

Mar 9, 2026, 7:00 AM EDT - 12 days ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NCEL

Mar 4, 2026, 4:05 PM EST - 17 days ago

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Feb 5, 2026, 4:10 PM EST - 6 weeks ago

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 23, 2026, 7:00 AM EST - 2 months ago

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Jan 8, 2026, 4:05 PM EST - 2 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Dec 1, 2025, 7:00 AM EST - 3 months ago

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 18, 2025, 4:05 PM EST - 4 months ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Nov 17, 2025, 1:07 PM EST - 4 months ago

Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 14, 2025, 5:00 PM EST - 4 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 12, 2025, 7:56 AM EST - 4 months ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 11, 2025, 5:26 PM EST - 4 months ago

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 7, 2025, 2:36 PM EST - 4 months ago

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript

Nov 7, 2025, 1:36 PM EST - 4 months ago

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Nov 6, 2025, 6:30 PM EST - 4 months ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Nov 5, 2025, 7:00 AM EST - 4 months ago

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Oct 17, 2025, 7:00 AM EDT - 5 months ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Sep 24, 2025, 4:05 PM EDT - 6 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Aug 29, 2025, 7:00 AM EDT - 7 months ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 14, 2025, 4:20 PM EDT - 7 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 6, 2025, 4:01 PM EDT - 8 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Jul 30, 2025, 4:05 PM EDT - 8 months ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 8 months ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jun 25, 2025, 4:01 PM EDT - 9 months ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

May 14, 2025, 4:01 PM EDT - 11 months ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 6, 2025, 1:15 PM EDT - 11 months ago

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

GEVO IRDM LPG

May 3, 2025, 8:15 AM EDT - 11 months ago

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 4, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Jan 29, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 28, 2025, 11:27 AM EST - 1 year ago

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Jan 13, 2025, 7:00 AM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Oct 29, 2024, 3:51 PM EDT - 1 year ago

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29, 2024, 7:46 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

May 9, 2024, 7:30 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 2 years ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 25, 2024, 4:56 PM EDT - 2 years ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

BlakeLawrence90 Mar. 21 at 4:56 PM

$ELDN small biotech setup with squeeze risk and the tape needs to prove it with real flow

0 · Reply

Cosmoskeeper Mar. 21 at 12:09 AM

$ELDN trials 👍🏻

0 · Reply

goooooolddust Mar. 20 at 10:51 PM

$ELDN it's opex Day guys, I don't think it added anything more than to do with that

0 · Reply

red1 Mar. 20 at 10:33 PM

$ELDN $SANA $VRTX what do you guys think? Why such big moves?

1 · Reply

red1 Mar. 20 at 9:05 PM

$ELDN $VRTX $SANA All had massive volume spike at the end… big volume AH … I wonder why? Islet act? Partnership collab?

0 · Reply

Penny_stock_Raid_Boss Mar. 20 at 8:43 PM

$ELDN casual almost 1 milly shares gap up in post market.

0 · Reply

Veraton Mar. 20 at 8:12 PM

$ELDN first time around here...mmm 🤔

0 · Reply

red1 Mar. 20 at 8:08 PM

$ELDN speculation I could be wrong of course . Let’s hope someone knows a thing or two

0 · Reply

red1 Mar. 20 at 8:03 PM

$ELDN the share at the end were for calll options wich get exercised automatically at close

0 · Reply

Veraton Mar. 20 at 8:01 PM

$ELDN 1.6 million shares last 5 seconds before the bell... Somebody knows something

0 · Reply

Ontherag Mar. 20 at 8:01 PM

$ELDN 3.3M

0 · Reply

KingofOptions Mar. 20 at 7:31 PM

$ELDN I see some many people with a long track record of Bag Holding stocks in this CRAP that is never a good sign. This many Bad Traders all in the same ticker! You can't make this crap up! This is almost a guaranteed sign to go down!

2 · Reply

TRISTANX17 Mar. 20 at 4:19 PM

$ELDN nice movement

0 · Reply

Veraton Mar. 19 at 9:42 PM

$ELDN Just came out in Yahoo finance... I didn't know the orphan drug designation covered the als part Announced that tegoprubart has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the prevention of allograft rejection in liver transplantation. Tegoprubart previously received Orphan Drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). Receive FDA regulatory guidance on path to market for tegoprubart in islet cell transplantation and xenotransplantation. Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients with renal dysfunction receiving an islet cell transplant. Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo liver transplant.

0 · Reply

Penny_stock_Raid_Boss Mar. 19 at 9:34 PM

$ELDN

0 · Reply

Veraton Mar. 19 at 7:56 PM

$ELDN Another thing Last week ah .15-.20 upside to open the next day same average of closing price or even under... Giving away ah gains... Why just don't buy during regular trading

1 · Reply

Veraton Mar. 19 at 7:47 PM

$ELDN I don't get it... Earning don't matter at this point Only cash reserves Forecast for 2026 And hints of future progress in pipelines....

1 · Reply

DonCorleone77 Mar. 19 at 7:25 PM

$ELDN Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings Pre-earnings options volume in Eledon Pharmaceuticals is normal with calls leading puts 724:1. Implied volatility suggests the market is anticipating a move near 11.7%, or 34c, after results are released. Median move over the past eight quarters is 4.5%.

1 · Reply

BriOnH Mar. 19 at 5:20 PM

$SANA $ELDN

1 · Reply

Sheajones Mar. 19 at 8:12 AM

$ELDN Only took 5 and a half years and a few hundred million for a 10 patient study result. ELDN Management should be taken out for a day of electro shock therapy. Only needs a 700% move up from here to get back to break even for many long term investors. So spare us your excitement, we've been down this road 2700 times the past 5 years with this imbecilic management team that is controlled and manipulated by their investment bankers.

1 · Reply

artynonymous Mar. 19 at 6:21 AM

$ELDN Hi new money making friends! Let's all get huge tax bills together!

0 · Reply

Veraton Mar. 19 at 2:59 AM

$ELDN this announcement is not speculation, this is real validation

0 · Reply

Market Cap	172.60M
Revenue (ttm)	0.00
Net Income (ttm)	-36.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,028,600
Avg Vol	983,254
Day's Range	N/A - N/A
Shares Out	59.93M
Stochastic %K	45%
Beta	0.84
Analysts	Strong Sell
Price Target	$8.00